Document is current
Any future updates will be listed below
-
Authors
Anzueto, Antonio
Rogers, Sheri
Donato, Bonnie
Jones, Beverly
Modi, Kushal
Olopoenia, Abisola
Wise, Robert
-
Funding
Funding for this research was provided by:
Boehringer Ingelheim Pharmaceuticals Inc.
- License Information
-
More Information
Article History
Received: 23 January 2024
Accepted: 31 July 2024
First Online: 17 August 2024
Declarations
:
: This study was conducted in compliance with the principles of the Declaration of Helsinki and the Guidelines for Good Pharmacoepidemiology Practice. The study was reviewed and approved by the Pearl Institutional Review Board (Indianapolis, IN, USA; 19-KANT-204).
: Not applicable.
: S.R., B.D., and B.J. are employees of BIPI. A.A. reports speaking fees from BIPI, AstraZeneca, Grifols, and Novartis and consulting fees from BIPI, GlaxoSmithKline, Sunovion, Novartis, and Grifols. R.W. reports consulting fees from BIPI, GlaxoSmithKline, AstraZeneca, Sanofi, 4DX, Contrafect, Bristol Myers Squibb, Savara, Puretech, Chiesi, Pulmonx, Galderma, Roche, Regeneron, AbbVie, Merck, Circassia, Beyond Air, and Verona. K.M. and A.O. are employees of Cerner Enviza, which was contracted by BIPI for data analysis.
